ArticleFrontiers in surgery2025
Circulating cell-free DNA and tumor DNA dynamics in obstructive colon cancer undergoing neoadjuvant chemotherapy following stent placement.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To improve the prognosis of patients with obstructive colon cancer, performing neoadjuvant chemotherapy after self-expanding metallic stent (SEMS) placement followed by elective surgery is currently one of the treatment methods for obstructive colon cancer. However, the oncological risks of this treatment approach are currently unclear. To evaluate the oncological risks of this treatment model by detecting changes in circulating cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) during the stent placement combined with neoadjuvant chemotherapy process. Methods: From January to December 2023, 10 patients with obstructive colon cancer who received neoadjuvant chemotherapy after SEMS placement, followed by surgical treatment, were included in this study. Blood samples were collected one day before stent placement, 3 days after stent placement, one day before surgery, and one day after surgery. cfDNA and ctDNA in the blood were detected and analyzed. Results: The stent placement success rate was 100%, with no cases of perforation, displacement, or re-obstruction, and no perioperative deaths. After neoadjuvant chemotherapy, peripheral ctDNA decreased compared to before stent placement. There were no statistically significant differences in cfDNA and ctDNA changes at the four time points during the treatment process. Conclusions: This study did not find an increase in ctDNA after stent placement combined with chemotherapy, suggesting that the model of stent placement combined with neoadjuvant chemotherapy for obstructive colon cancer may be a safe and reliable therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.